One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Sodium–glucose co-transporter 2 inhibition: the saga continues
Filippo Crea
doi : 10.1093/eurheartj/ehac590
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4215–4218
Empagliflozin in patients hospitalized for acute heart failureÂ
Piotr Ponikowski, Jan Biegus
doi : 10.1093/eurheartj/ehac427
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4219–4221
The promise and pitfalls of novel cuffless blood pressure devicesÂ
Aletta E Schutte
doi : 10.1093/eurheartj/ehac474
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4222–4223
Resounding victory in golf of the Continental Europe Team of CardiologyÂ
Peter J Schwartz, Paolo Pantaleo, Gian Paolo Bezante
doi : 10.1093/eurheartj/ehac392
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4224–4226
Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscapeÂ
Daniela Pedicino, Massimo Volpe
doi : 10.1093/eurheartj/ehac502
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4227–4228
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
Alexander R Lyon, Teresa López-Fernández, Liam S Couch, Riccardo Asteggiano, Marianne C Aznar, Jutta Bergler-Klein, Giuseppe Boriani, Daniela Cardinale, Raul Cordoba, Bernard Cosyns, David J Cutter, Evandro de Azambuja, Rudolf A de Boer, Susan F Dent, Dimitrios Farmakis, Sofie A Gevaert, Diana A Gorog, Joerg Herrmann, Daniel Lenihan, Javid Moslehi, Brenda Moura, Sonja S Salinger, Richard Stephens, Thomas M Suter, Sebastian Szmit, Juan Tamargo, Paaladinesh Thavendiranathan, Carlo G Tocchetti, Peter van der Meer, Helena J H van der Pal, ESC Scientific Document Group
doi : 10.1093/eurheartj/ehac244
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4229–4361
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trialÂ
Javed Butler, Stefan D Anker, Lars H Lund, Andrew J S Coats, Gerasimos Filippatos, Tariq Jamal Siddiqi, Tim Friede, Vincent Fabien, Mikhail Kosiborod, Marco Metra, Ileana L Piña, Fausto Pinto, Patrick Rossignol, Peter van der Meer, Cecilia Bahit, Jan Belohlavek, Michael Böhm, Jasper J Brugts, John G F Cleland, Justin Ezekowitz, Antoni Bayes-Genis, Israel Gotsman, Assen Goudev, Irakli Khintibidze, Joann Lindenfeld, Robert J Mentz, Bela Merkely, Eliodoro Castro Montes, Wilfried Mullens, Jose C Nicolau, Aleksandr Parkhomenko, Piotr Ponikowski, Petar M Seferovic, Michele Senni, Evgeny Shlyakhto, Alain Cohen-Solal, Peter Szecsödy, Klaus Jensen, Fabio Dorigotti, Matthew R Weir, Bertram Pitt
doi : 10.1093/eurheartj/ehac401
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4362–4373
To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin–angiotensin–aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF).
Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trialÂ
Milton Packer
doi : 10.1093/eurheartj/ehac399
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4374–4377
Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trialÂ
Henrique Andrade R Fonseca, Remo Holanda M Furtado, André Zimerman, Pedro A Lemos, Marcelo Franken, Frederico Monfardini, Rodrigo P Pedrosa, Rodrigo de Lemos S Patriota, Luiz Carlos S Passos, Frederico Toledo C Dall’Orto, Conrado R Hoffmann Filho, Bruno Ramos Nascimento, Felipe A Baldissera, Cesar Augusto C Pereira, Paulo Ricardo A Caramori, Pedro Beraldo de Andrade, Carlos Esteves, Elke Ferreira Salim, Jefferson Henrique da Silva, Izabela Chave Pedro, Mariana Castaldi R Silva, Ewerton Hernandes de Pedri, Ana Carla R D Carioca, Luciana Pereira A de Piano, Camila Santos N Albuquerque, Diogo D F Moia, Roberta Grazzielli R A P Momesso, Felipe P Machado, Lucas P Damiani, Ronaldo Vicente P Soares, Guilherme P Schettino, Luiz V Rizzo, José Carlos Nicolau, Otávio Berwanger on behalf of the VIP-ACS Study Investigators
doi : 10.1093/eurheartj/ehac472
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4378–4388
To evaluate whether a strategy of double-dose influenza vaccination during hospitalization for an acute coronary syndrome (ACS) compared with standard-dose outpatient vaccination (as recommended by current guidelines) would further reduce the risk of major cardiopulmonary events.
Influenza vaccine in cardiovascular disease: time to move the needleÂ
Orly Vardeny
doi : 10.1093/eurheartj/ehac491
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4389–4391
Cost effectiveness of population screening vs. no screening for cardiovascular disease: the Danish Cardiovascular Screening trial (DANCAVAS)Â
Rikke Søgaard, Axel Cosmus Pyndt Diederichsen, Lars M Rasmussen, Jess Lambrechtsen, Flemming H Steffensen, Lars Frost, Kenneth Egstrup, Grazina Urbonaviciene, Martin Busk, Jes S Lindholt
doi : 10.1093/eurheartj/ehac488
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4392–4402
A recent trial has shown that screening of men for cardiovascular disease (CVD) may reduce all-cause mortality. This study assesses the cost effectiveness of such screening vs. no screening from the perspective of European healthcare systems.
Economic value of multimodal cardiovascular screeningÂ
Mark A Hlatky, Philip Greenland
doi : 10.1093/eurheartj/ehac489
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4403–4405
Dapagliflozin for heart failure according to body mass index: the DELIVER trialÂ
Carly Adamson, Toru Kondo, Pardeep S Jhund, Rudolf A de Boer, Jose Walter Cabrera Honorio, Brian Claggett, Akshay S Desai, Marco Antonio Alcocer Gamba, Waleed Al Habeeb, Adrian F Hernandez, Silvio E Inzucchi, Mikhail N Kosiborod, Carolyn S P Lam, Anna Maria Langkilde, Daniel Lindholm, Erasmus Bachus, Sheldon E Litwin, Felipe Martinez, Magnus Petersson, Sanjiv J Shah, Muthiah Vaduganathan, Pham Nguyen Vinh, Ulrica Wilderäng, Scott D Solomon, John J V McMurray
doi : 10.1093/eurheartj/ehac481
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4406–4417
Obesity is common and associated with unique phenotypic features in heart failure with preserved ejection fraction (HFpEF). Therefore, understanding the efficacy and safety of new therapies in HFpEF patients with obesity is important.
‘Normal weight’ is really not normal in chronic diseaseÂ
Stefan D Anker, Muhammad Shariq Usman, Javed Butler
doi : 10.1093/eurheartj/ehac486
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4418–4420
Empagliflozin in acute myocardial infarction: the EMMY trialÂ
Dirk von Lewinski, Ewald Kolesnik, Norbert J Tripolt, Peter N Pferschy, Martin Benedikt, Markus Wallner, Hannes Alber, Rudolf Berger, Michael Lichtenauer, Christoph H Saely, Deddo Moertl, Pia Auersperg, Christian Reiter, Thomas Rieder, Jolanta M Siller-Matula, Gloria M Gager, Matthias Hasun, Franz Weidinger, Thomas R Pieber, Peter M Zechner, Markus Herrmann, Andreas Zirlik, Rury R Holman, Abderrahim Oulhaj, Harald Sourij
doi : 10.1093/eurheartj/ehac494
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4421–4432
Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart failure and for death in patients with symptomatic heart failure. However, trials investigating the effects of this drug class in patients following acute myocardial infarction are lacking.
Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failureÂ
Josephine Harrington, Stefan Anker, Javed Butler
doi : 10.1093/eurheartj/ehac483
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4433–4435
Hypernatremia and subclinical chronic kidney diseaseÂ
Pantelis Sarafidis, Charles J Ferro, Alberto Ortiz
doi : 10.1093/eurheartj/ehac367
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4436–4437
Making decision about fluid intake: increase or not increaseÂ
Natalia I Dmitrieva, Douglas R Rosing, Manfred Boehm
doi : 10.1093/eurheartj/ehac368
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4438–4439
A case of bilateral atrial myxoma straddling the foramen ovale
Jun He, Juan Xia, Xiaojing Ma
doi : 10.1093/eurheartj/ehac386
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Page 4440
Pulmonary artery aneurysm and dissection caused by patent ductus arteriosus
Huawei Zhang, Chengxin Weng, Ding Yuan, Tiehao Wang
doi : 10.1093/eurheartj/ehac438
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Page 4441
Erratum to: Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
doi : 10.1093/eurheartj/ehac425
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Page 4391
Corrigendum to: Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator
doi : 10.1093/eurheartj/ehac452
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Page 4373
Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled
doi : 10.1093/eurheartj/ehac428
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Page 4377
